BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29795241)

  • 1. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
    Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
    Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality.
    Sumarriva Lezama L; Chisholm KM; Carneal E; Nagy A; Cascio MJ; Yan J; Chang CC; Cherry A; George TI; Ohgami RS
    Histopathology; 2018 Nov; 73(5):767-776. PubMed ID: 29884995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations.
    Sakamoto K; Takeuchi K
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):523-538. PubMed ID: 32336417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Ceribelli M; Hou ZE; Kelly PN; Huang DW; Wright G; Ganapathi K; Evbuomwan MO; Pittaluga S; Shaffer AL; Marcucci G; Forman SJ; Xiao W; Guha R; Zhang X; Ferrer M; Chaperot L; Plumas J; Jaffe ES; Thomas CJ; Reizis B; Staudt LM
    Cancer Cell; 2016 Nov; 30(5):764-778. PubMed ID: 27846392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CD56- immunoblastoid variant of blastic plasmacytoid dendritic cell neoplasm.
    Aran BM; Duran J; Whittemore D; Gru AA
    J Cutan Pathol; 2024 Jan; 51(1):40-44. PubMed ID: 37612885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms.
    Boddu PC; Wang SA; Pemmaraju N; Tang Z; Hu S; Li S; Xu J; Medeiros LJ; Tang G
    Leuk Res; 2018 Mar; 66():73-78. PubMed ID: 29407586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of 46 cases with CD4
    Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
    Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Khoury JD
    Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.
    Julia F; Petrella T; Beylot-Barry M; Bagot M; Lipsker D; Machet L; Joly P; Dereure O; Wetterwald M; d'Incan M; Grange F; Cornillon J; Tertian G; Maubec E; Saiag P; Barete S; Templier I; Aubin F; Dalle S
    Br J Dermatol; 2013 Sep; 169(3):579-86. PubMed ID: 23646868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
    Zhang X; Sun J; Yang M; Wang L; Jin J
    Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
    Lim MS; Lemmert K; Enjeti A
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
    Cheng W; Yu TT; Tang AP; He Young K; Yu L
    Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blastic plasmacytoid dendritic cell neoplasm with immunoblastoid morphology and MYC rearrangement and overexpression.
    Chang KC; Yu-Yun Lee J; Sakamoto K; Baba S; Takeuchi K
    Pathology; 2019 Jan; 51(1):100-102. PubMed ID: 30482401
    [No Abstract]   [Full Text] [Related]  

  • 14. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events.
    Tang Z; Li Y; Wang W; Yin CC; Tang G; Aung PP; Hu S; Lu X; Toruner GA; Medeiros LJ; Khoury JD
    Leuk Res; 2018 Oct; 73():86-94. PubMed ID: 30248580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.
    Bastidas Torres AN; Cats D; Mei H; Fanoni D; Gliozzo J; Corti L; Paulli M; Vermeer MH; Willemze R; Berti E; Tensen CP
    Genes Chromosomes Cancer; 2020 May; 59(5):295-308. PubMed ID: 31846142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling.
    Rethnam M; Tan DQ; Tan SH; Li J; Yokomori R; Li Y; Yang H; Sanda T; Suda T
    Blood Adv; 2022 Sep; 6(18):5330-5344. PubMed ID: 35482445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm.
    Yang N; Huh J; Chung WS; Cho MS; Ryu KH; Chung HS
    Cancer Genet; 2015 Sep; 208(9):464-7. PubMed ID: 26164398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
    Emadali A; Hoghoughi N; Duley S; Hajmirza A; Verhoeyen E; Cosset FL; Bertrand P; Roumier C; Roggy A; Suchaud-Martin C; Chauvet M; Bertrand S; Hamaidia S; Rousseaux S; Josserand V; Charles J; Templier I; Maeda T; Bruder-Costa J; Chaperot L; Plumas J; Jacob MC; Bonnefoix T; Park S; Gressin R; Tensen CP; Mecucci C; Macintyre E; Leroux D; Brambilla E; Nguyen-Khac F; Luquet I; Penther D; Bastard C; Jardin F; Lefebvre C; Garnache F; Callanan MB
    Blood; 2016 Jun; 127(24):3040-53. PubMed ID: 27060168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
    Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
    Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.